Semin Reprod Med 2008; 26(1): 045-052
DOI: 10.1055/s-2007-992924
© Thieme Medical Publishers

Mood and Sexual Function in Polycystic Ovary Syndrome

Onno E. Janssen1 , Susanne Hahn2 , Susanne Tan3 , Sven Benson4 , Sigrid Elsenbruch4
  • 1Division of Endocrinology, Metabolism and Molecular Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
  • 2Praxis für Endokrinologie, Wuppertal, Germany
  • 3Division of Endocrinology, Department of Medicine, University Hospital of Essen Medical School, Essen, Germany
  • 4Institute of Medical Psychology, University Hospital of Essen Medical School, Essen, Germany
Further Information

Publication History

Publication Date:
08 January 2008 (online)

ABSTRACT

Women with polycystic ovary syndrome (PCOS) fail to conform with societal norms for outer appearance. Many PCOS patients thus feel stigmatized in the sense of a loss of “feminine identity.” In addition to somatic impairment, mood disturbances such as depression and limitations in emotional well-being, quality of life, and life satisfaction, the diagnosis of PCOS also has a negative impact on sexual self-worth and sexual satisfaction. Both obesity and hirsutism are major determinants of the physical component of quality of life in affected women. However, its psychological aspect appears to be inherent and specific for PCOS. Confirmation of the diagnosis and provision of detailed information to affected women, together with the availability of interdisciplinary treatment aimed at improving PCOS-related symptoms, such as hirsutism, obesity, menstrual irregularity, and infertility, will also reduce psychological distress and improve sexual self-worth. New treatment options, including insulin sensitizers, psychological counseling, and participation in a PCOS support group, are likely to further improve life satisfaction and coping of affected women.

REFERENCES

  • 1 WHO .Development and Constitution of the W.H.O. Geneva. Switzerlandm; United Nations 1947
  • 2 WHO Division of Mental Health .WHO-QOL Study Protocol: The Development of the World Health Organization Quality of Life Assessment Instrument. Geneva, Switzerland; United Nations 1993
  • 3 Ferrell B, Grant M, Padilla G, Vemuri S, Rhiner M. The experience of pain and perceptions of quality of life: validation of a conceptual model.  Hosp J. 1991;  7 9-24
  • 4 Diamanti-Kandarakis E, Kouli C R, Bergiele A T et al.. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile.  J Clin Endocrinol Metab. 1999;  84 4006-4011
  • 5 Asuncion M, Calvo R M, San Millan J L, Sancho J, Avila S, Escobar-Morreale H F. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain.  J Clin Endocrinol Metab. 2000;  85 2434-2438
  • 6 Azziz R, Woods K S, Reyna R, Key T J, Knochenhauer E S, Yildiz B O. The prevalence and features of the polycystic ovary syndrome in an unselected population.  J Clin Endocrinol Metab. 2004;  89 2745-2749
  • 7 Ehrmann D A. Polycystic ovary syndrome.  N Engl J Med. 2005;  352 1223-1236
  • 8 Hahn S, Tan S, Elsenbruch S et al.. Clinical and biochemical characterization of women with polycystic ovary syndrome in North Rhine-Westphalia.  Horm Metab Res. 2005;  37 438-444
  • 9 Elsenbruch S, Benson S, Hahn S et al.. Determinants of emotional distress in women with polycystic ovary syndrome.  Hum Reprod. 2006;  21 1092-1099
  • 10 Avery J C, Braunack-Mayer A J. The information needs of women diagnosed with polycystic ovarian syndrome-implications for treatment and health outcomes.  BMC Womens Health. 2007;  7 9
  • 11 Ching H L, Burke V, Stuckey B G. Quality of life and psychological morbidity in women with polycystic ovary syndrome: body mass index, age and the provision of patient information are significant modifiers.  Clin Endocrinol (Oxf). 2007;  66 373-379
  • 12 Dunaif A, Thomas A. Current concepts in the polycystic ovary syndrome.  Annu Rev Med. 2001;  52 401-419
  • 13 Escobar-Morreale H F, Luque-Ramirez M, San Millan J L. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome.  Endocr Rev. 2005;  26 251-282
  • 14 Azziz R. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature.  J Clin Endocrinol Metab. 2006;  91 781-785
  • 15 Zawadski J K, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR Polycystic Ovary Syndrome. Boston; Blackwell Scientific 1992: 377-384
  • 16 The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group . Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).  Hum Reprod. 2004;  19 41-47
  • 17 Himelein M J, Thatcher S S. Polycystic ovary syndrome and mental health: a review.  Obstet Gynecol Surv. 2006;  61 723-732
  • 18 Eggers S, Kirchengast S. The polycystic ovary syndrome-a medical condition but also an important psychosocial problem.  Coll Antropol. 2001;  25 673-685
  • 19 Kitzinger C, Willmott J. ‘The thief of womanhood’: women's experience of polycystic ovarian syndrome.  Soc Sci Med. 2002;  54 349-361
  • 20 Sills E S, Perloe M, Tucker M J, Kaplan C R, Genton M G, Schattman G L. Diagnostic and treatment characteristics of polycystic ovary syndrome: descriptive measurements of patient perception and awareness from 657 confidential self-reports.  BMC Womens Health. 2001;  1 3
  • 21 Trent M E, Rich M, Austin S B, Gordon C M. Quality of life in adolescent girls with polycystic ovary syndrome.  Arch Pediatr Adolesc Med. 2002;  156 556-560
  • 22 Trent M, Austin S B, Rich M, Gordon C M. Overweight status of adolescent girls with polycystic ovary syndrome: body mass index as mediator of quality of life.  Ambul Pediatr. 2005;  5 107-111
  • 23 Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study.  Clin Endocrinol (Oxf). 2000;  52 595-600
  • 24 Legro R S. Polycystic ovary syndrome and cardiovascular disease: a premature association?.  Endocr Rev. 2003;  24 302-312
  • 25 Cronin L, Guyatt G, Griffith L et al.. Development of a health-related quality-of-life questionnaire (PCOSQ) for women with polycystic ovary syndrome (PCOS).  J Clin Endocrinol Metab. 1998;  83 1976-1987
  • 26 Jones G L, Benes K, Clark T L et al.. The Polycystic Ovary Syndrome Health-Related Quality of Life Questionnaire (PCOSQ): a validation.  Hum Reprod. 2004;  19 371-377
  • 27 Coffey S, Bano G, Mason H D. Health-related quality of life in women with polycystic ovary syndrome: a comparison with the general population using the Polycystic Ovary Syndrome Questionnaire (PCOSQ) and the Short Form-36 (SF-36).  Gynecol Endocrinol. 2006;  22 80-86
  • 28 Guyatt G, Weaver B, Cronin L, Dooley J A, Azziz R. Health-related quality of life in women with polycystic ovary syndrome, a self-administered questionnaire, was validated.  J Clin Epidemiol. 2004;  57 1279-1287
  • 29 Schmid J, Kirchengast S, Vytiska-Binstorfer E, Huber J. Infertility caused by PCOS-health-related quality of life among Austrian and Moslem immigrant women in Austria.  Hum Reprod. 2004;  19 2251-2257
  • 30 Pekhlivanov B, Kolarov G, Kavurdzhikova S, Stoikov S. Determinants of health related quality of life in women with polycystic ovary syndrome [in Bulgarian].  Akush Ginekol (Sofiia). 2006;  45 29-34
  • 31 Zung W WA. Self-Rating Depression Scale.  Arch Gen Psychiatry. 1965;  12 63-70
  • 32 Barnard L, Ferriday D, Guenther N, Strauss B, Balen A H, Dye L. Quality of life and psychological well being in polycystic ovary syndrome.  Hum Reprod. 2007;  22 2279-2286
  • 33 Elsenbruch S, Hahn S, Kowalsky D et al.. Quality of life, psychosocial well-being, and sexual satisfaction in women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2003;  88 5801-5807
  • 34 Ware Jr J E, Sherbourne C D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.  Med Care. 1992;  30 473-483
  • 35 McHorney C A, Ware Jr J E, Raczek A E. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs.  Med Care. 1993;  31 247-263
  • 36 Schmitz N, Hartkamp N, Kiuse J, Franke G H, Reister G, Tress W. The Symptom Check-List-90-R (SCL-90-R): a German validation study.  Qual Life Res. 2000;  9 185-193
  • 37 Derogatis L R, Rickels K, Rock A F. The SCL-90 and the MMPI: a step in the validation of a new self-report scale.  Br J Psychiatry. 1976;  128 280-289
  • 38 Henrich G, Herschbach P. Questions on life satisfaction (FLZ) - A short questionnaire for assessing subjective quality of life.  Eur J Psychol Assess. 2000;  16 150-159
  • 39 Goldbeck L, Schmitz T G. Comparison of three generic questionnaires measuring quality of life in adolescents and adults with cystic fibrosis: the 36-item short form health survey, the quality of life profile for chronic diseases, and the questions on life satisfaction.  Qual Life Res. 2001;  10 23-36
  • 40 Sonino N, Fava G A, Mani E, Belluardo P, Boscaro M. Quality of life of hirsute women.  Postgrad Med J. 1993;  69 186-189
  • 41 Loo W J, Lanigan S W. Laser treatment improves quality of life of hirsute females.  Clin Exp Dermatol. 2002;  27 439-441
  • 42 Hahn S, Janssen O E, Tan S et al.. Clinical and psychological correlates of quality-of-life in polycystic ovary syndrome.  Eur J Endocrinol. 2005;  153 853-860
  • 43 Keegan A, Liao L M, Boyle M. ‘Hirsutism’: a psychological analysis.  J Health Psychol. 2003;  8 327-345
  • 44 Barth J H, Catalan J, Cherry C A, Day A. Psychological morbidity in women referred for treatment of hirsutism.  J Psychosom Res. 1993;  37 615-619
  • 45 Shulman L H, DeRogatis L, Spielvogel R, Miller J L, Rose L I. Serum androgens and depression in women with facial hirsutism.  J Am Acad Dermatol. 1992;  27(2 Pt 1) 178-181
  • 46 Coffey S, Mason H. The effect of polycystic ovary syndrome on health-related quality of life.  Gynecol Endocrinol. 2003;  17 379-386
  • 47 Klassen A F, Newton J N, Mallon E. Measuring quality of life in people referred for specialist care of acne: comparing generic and disease-specific measures.  J Am Acad Dermatol. 2000;  43(2 Pt 1) 229-233
  • 48 Mallon E, Newton J N, Klassen A, Stewart-Brown S L, Ryan T J, Finlay A Y. The quality of life in acne: a comparison with general medical conditions using generic questionnaires.  Br J Dermatol. 1999;  140 672-676
  • 49 Yazici K, Baz K, Yazici A E et al.. Disease-specific quality of life is associated with anxiety and depression in patients with acne.  J Eur Acad Dermatol Venereol. 2004;  18 435-439
  • 50 Dolte K S, Girman C J, Hartmaier S, Roberts J, Bergfeld W, Waldstreicher J. Development of a health-related quality of life questionnaire for women with androgenetic alopecia.  Clin Exp Dermatol. 2000;  25 637-642
  • 51 Girman C J, Hartmaier S, Roberts J, Bergfeld W, Waldstreicher J. Patient-perceived importance of negative effects of androgenetic alopecia in women.  J Womens Health Gend Based Med. 1999;  8 1091-1095
  • 52 Van Der Donk J, Hunfeld J A, Passchier J, Knegt-Junk K J, Nieboer C. Quality of life and maladjustment associated with hair loss in women with alopecia androgenetica.  Soc Sci Med. 1994;  38 159-163
  • 53 Paoletti A M, Floris S, Mannias M et al.. Evidence that cyproterone acetate improves psychological symptoms and enhances the activity of the dopaminergic system in postmenopause.  J Clin Endocrinol Metab. 2001;  86 608-612
  • 54 Weiner C L, Primeau M, Ehrmann D A. Androgens and mood dysfunction in women: comparison of women with polycystic ovarian syndrome to healthy controls.  Psychosom Med. 2004;  66 356-362
  • 55 Goldstat R, Briganti E, Tran J, Wolfe R, Davis S R. Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women.  Menopause. 2003;  10 390-398
  • 56 Shifren J L, Braunstein G D, Simon J A et al.. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy.  N Engl J Med. 2000;  343 682-688
  • 57 Floter A, Nathorst-Boos J, Carlstrom K, von Schoultz B. Addition of testosterone to estrogen replacement therapy in oophorectomized women: effects on sexuality and well-being.  Climacteric. 2002;  5 357-365
  • 58 Sherwin B B, Gelfand M M, Brender W. Androgen enhances sexual motivation in females: a prospective, crossover study of sex steroid administration in the surgical menopause.  Psychosom Med. 1985;  47 339-351
  • 59 Paulson J D, Haarmann B S, Salerno R L, Asmar P. An investigation of the relationship between emotional maladjustment and infertility.  Fertil Steril. 1988;  49 258-262
  • 60 Trent M E, Rich M, Austin S B, Gordon C M. Fertility concerns and sexual behavior in adolescent girls with polycystic ovary syndrome. Implications for quality of life.  J Pediatr Adolesc Gynecol. 2003;  16 33-37
  • 61 Monga M, Alexandrescu B, Katz S E, Stein M, Ganiats T. Impact of infertility on quality of life, marital adjustment, and sexual function.  Urology. 2004;  63 126-130
  • 62 Wischmann T, Stammer H, Scherg H, Gerhard I, Verres R. Psychosocial characteristics of infertile couples: a study by the ‘Heidelberg Fertility Consultation Service’.  Hum Reprod. 2001;  16 1753-1761
  • 63 Ragni G, Mosconi P, Baldini M P et al.. Health-related quality of life and need for IVF in 1000 Italian infertile couples.  Hum Reprod. 2005;  20 1286-1291
  • 64 Himelein M J, Thatcher S S. Depression and body image among women with polycystic ovary syndrome.  J Health Psychol. 2006;  11 613-625
  • 65 Ardenti R, Campari C, Agazzi L, La Sala G B. Anxiety and perceptive functioning of infertile women during in-vitro fertilization: exploratory survey of an Italian sample.  Hum Reprod. 1999;  14 3126-3132
  • 66 Chiba H, Mori E, Morioka Y et al.. Stress of female infertility: relations to length of treatment.  Gynecol Obstet Invest. 1997;  43 171-177
  • 67 Guerra D, Llobera A, Veiga A, Barri P N. Psychiatric morbidity in couples attending a fertility service.  Hum Reprod. 1998;  13 1733-1736
  • 68 Oddens B J, den Tonkelaar I, Nieuwenhuyse H. Psychosocial experiences in women facing fertility problems-a comparative survey.  Hum Reprod. 1999;  14 255-261
  • 69 Boivin J, Takefman J E, Tulandi T, Brender W. Reactions to infertility based on extent of treatment failure.  Fertil Steril. 1995;  63 801-807
  • 70 Fekkes M, Buitendijk S E, Verrips G H et al.. Health-related quality of life in relation to gender and age in couples planning IVF treatment.  Hum Reprod. 2003;  18 1536-1543
  • 71 McCook J G, Reame N E, Thatcher S S. Health-related quality of life issues in women with polycystic ovary syndrome.  J Obstet Gynecol Neonatal Nurs. 2005;  34 12-20
  • 72 Stunkard A J, Faith M S, Allison K C. Depression and obesity.  Biol Psychiatry. 2003;  54 330-337
  • 73 Mannucci E, Ricca V, Barciulli E et al.. Quality of life and overweight: the obesity related well-being (Orwell 97) questionnaire.  Addict Behav. 1999;  24 345-357
  • 74 Swallen K C, Reither E N, Haas S A, Meier A M. Overweight, obesity, and health-related quality of life among adolescents: the National Longitudinal Study of Adolescent Health.  Pediatrics. 2005;  115 340-347
  • 75 Hashimoto D M, Schmid J, Martins F M et al.. The impact of the weight status on subjective symptomatology of the polycystic ovary syndrome: a cross-cultural comparison between Brazilian and Austrian women.  Anthropol Anz. 2003;  61 297-310
  • 76 Faith M S, Matz P E, Jorge M A. Obesity-depression associations in the population.  J Psychosom Res. 2002;  53 935-942
  • 77 Onyike C U, Crum R M, Lee H B, Lyketsos C G, Eaton W W. Is obesity associated with major depression? Results from the Third National Health and Nutrition Examination Survey.  Am J Epidemiol. 2003;  158 1139-1147
  • 78 Derogatis L R, Rose L I, Shulman L H, Lazarus L A. Serum androgens and psychopathology in hirsute women.  J Psychosom Obstet Gynaecol. 1993;  14 269-282
  • 79 Cecchine R. Scrambled; a journey through polycystic ovarian syndrome.  Available at: http://scrambledthewebsite.com , Accessed February 11, 2007
  • 80 Matsunaga H, Sarai M. Elevated serum LH and androgens in affective disorder related to the menstrual cycle: with reference to polycystic ovary syndrome.  Jpn J Psychiatry Neurol. 1993;  47 825-842
  • 81 Bruce-Jones W, Zolese G, White P. Polycystic ovary syndrome and psychiatric morbidity.  J Psychosom Obstet Gynaecol. 1993;  14 111-116
  • 82 Dittmar M, Heintz A, Hardt J, Egle U T, Kahaly G J. Metabolic and psychosocial effects of minimal invasive gastric banding for morbid obesity.  Metabolism. 2003;  52 1551-1557
  • 83 Jalil R A, Manan W A, Bebakar W M, Halim R, Ooi G S, Othman R. Assessing changes in quality of life among obese participants in Kelantan, Malaysia.  Asia Pac J Clin Nutr. 2004;  13(Suppl) S141
  • 84 Mathus-Vliegen E M, de Weerd S, de Wit L T. Health-related quality-of-life in patients with morbid obesity after gastric banding for surgically induced weight loss.  Surgery. 2004;  135 489-497
  • 85 Ogden J, Clementi C, Aylwin S, Patel A. Exploring the impact of obesity surgery on patients' health status: a quantitative and qualitative study.  Obes Surg. 2005;  15 266-272
  • 86 Lord J M, Flight I H, Norman R J. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome.  Cochrane Database Syst Rev. 2003;  3 CD003053
  • 87 Hahn S, Benson S, Elsenbruch S et al.. Metformin treatment of polycystic ovary syndrome improves health-related quality-of-life, emotional distress and sexuality.  Hum Reprod. 2006;  21 1925-1934

Onno E JanssenM.D. 

Raalandsweg 36

22559 Hamburg, Germany

Email: onno@onnojanssen.de

    >